Vitalhub (VHI) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
13 Nov, 2025Executive summary
Achieved annual recurring revenue (ARR) of CAD 93.7 million, up 75% year-over-year as of September 30, 2025, nearing the CAD 100 million milestone, driven by acquisitions and FX.
Q3 revenue increased 94% year-over-year to CAD 32 million, with strong execution on integration plans and a focus on enhancing margins.
Adjusted EBITDA rose 58% year-over-year to CAD 7.2 million, representing 22% of revenue.
Two large acquisitions now represent 30% of revenue, with integration and cost reduction programs underway.
Focus remains on integrating recent acquisitions and pursuing organic growth and M&A opportunities.
Financial highlights
Q3 2025 revenue was CAD 32,044,030, up from CAD 16,509,135 in Q3 2024, a 94% increase.
Recurring revenue was CAD 23.6 million (74% of total), with virtual care term license revenue at CAD 2.5 million and petrol license revenue at CAD 500,000.
Gross margin held steady at 81% of revenue for both Q3 2025 and Q3 2024.
Adjusted EBITDA was CAD 7.2 million (22% of revenue), compared to CAD 4.6 million (28%) last year.
Cash on hand as of September 30, 2025, was CAD 123.8 million, more than double the December 31, 2024 balance, with no debt.
Outlook and guidance
Expect recurring revenue mix to return to historical levels as services revenue normalizes.
Integration and cost reduction from acquisitions to continue into 2026, with a goal to restore adjusted EBITDA margins to 26–28%.
Management continues to pursue organic growth and M&A opportunities, emphasizing commercial and operational alignment.
Anticipate new revenue and cost synergies to materialize over the next few quarters.
AI initiatives underway, with monetization expected in late 2026 or 2027.
Latest events from Vitalhub
- ARR and revenue surged in 2025, with strong EBITDA growth and cash for acquisitions.VHI
Q4 202519 Mar 2026 - Q2 revenue up 24% with 41% higher adjusted EBITDA and MedCurrent acquisition pending.VHI
Q2 20241 Feb 2026 - Growth through acquisitions and AI integration aims to boost recurring revenue and margins by 2026.VHI
2nd Annual Lytham Partners Healthcare Investor Summit15 Jan 2026 - Delivers $93.7M ARR and 22% EBITDA margin through global healthcare software and M&A.VHI
Investor presentation15 Jan 2026 - Q3 revenue and ARR up 25%, pro forma ARR at CAD 68M after acquisitions, strong cash position.VHI
Q3 202413 Jan 2026 - Healthcare IT firm achieves $70M+ ARR via acquisitions, organic growth, and high-margin solutions.VHI
Planet MicroCap Showcase: VEGAS 202527 Dec 2025 - ARR up 59% and revenue up 31% in 2024, with robust M&A and strong cash position.VHI
Q4 202426 Dec 2025 - Q1 2025 delivered robust ARR and revenue growth, with strong M&A momentum and cash position.VHI
Q1 202526 Nov 2025 - ARR up 55%, revenue up 47%, 26% EBITDA margin, and strong acquisition integration.VHI
Q2 202523 Nov 2025